Recently, the FDA issued a nuvaring label change. Apparently, a nuvaring label change was approved by the FDA Center for Drug Evaluation and Research (CDER) on October 2013. The nuvaring label change was related to Thromboembolic Disorders and Other Vascular Problems. In particular, the nuvaring label change stated the following: […]